RespireRx Pharmaceuticals Inc (RSPI):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:RespireRx Pharmaceuticals Inc (RSPI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10064
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
RespireRx Pharmaceuticals Inc (RespireRx), formerly Cortex Pharmaceuticals, Inc., focuses on the discovery, development and commercialization of innovative products for the treatment of various respiratory disorders. It has two drug platforms, each with a clinical stage compound directed at breathing disorders. The company’s respiratory disease product pipeline includes compounds in various development stages for the treatment of obstructive sleep apnea (OSA), chronic and post-surgical central sleep apnea (CSA), opioid induced respiratory depression, spinal cord injury, and induced respiratory depression. Its lead product, Dronabinol, an oral capsule drug product completed Phase II trials for the treatment of OSA. RespireRx is headquartered in Glen Rock, New Jersey, the US.

RespireRx Pharmaceuticals Inc (RSPI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
RespireRx Pharma Raises Funds through in Venture Financing 11
RespireRx Pharma Raises USD0.1 Million in Financing 12
Partnerships 13
RespireRx Pharma Enters into Agreement Noramco 13
RespireRx Pharma Enters into Research Agreement with National Institute of Drug Abuse 14
Licensing Agreements 15
Cortex Pharma Enters into Licensing Agreement with University of Illinois 15
Samyang Optics Enters into Licensing Agreement with Cortex Pharma 17
Equity Offering 18
Cortex Pharma Raises USD0.7 Million in First Tranche of Private Placement of Units 18
Acquisition 19
Cortex Pharma Acquires Pier Pharma, Sleep Apnea Drug Development Company 19
RespireRx Pharmaceuticals Inc – Key Competitors 20
RespireRx Pharmaceuticals Inc – Key Employees 21
RespireRx Pharmaceuticals Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Aug 25, 2017: RespireRx Pharmaceuticals Files June 30, 2017 Quarterly Report on Form 10-Q And Provides Update 23
Product News 25
12/06/2017: Synthetic Cannabis-like Drug Reduces Sleep Apnea 25
Jul 25, 2018: RespireRx Pharmaceuticals Announces Publication of Ampakine Data 27
01/06/2017: RespireRx Pharmaceuticals to Present Data on CX-717 at 9th Annual Biotech Showcase 2017 28
Clinical Trials 29
Jan 08, 2018: RespireRx Pharma to Present on Dronabinol at 10th Annual Biotech Showcase 2018 29
Jan 08, 2018: RespireRx Pharmaceuticals to on CX-1739 Present at 10th Annual Biotech Showcase 2018 30
Dec 18, 2017: RespireRx Pharmaceuticals Publishes Compelling Scientific Evidence Demonstrating the Neurobiological Safety of Ampakine CX717 and Justifying Continued Clinical Development 31
Nov 30, 2017: RespireRx Pharmaceuticals Announces Publication of Phase 2B PACE Study: Once per Night Treatment with Dronabinol Provides Statistically Significant Improvement in Clinical Measures of Obstructive Sleep Apnea 32
Sep 08, 2017: RespireRx Pharmaceuticals to Present Update on Phase IIB Trial of CX1739 at 2017 Rodman & Renshaw Conference 34
Sep 08, 2017: RespireRx’s CEO to Present Clinical Trial plans for Dronabinol at 2017 Rodman & Renshaw Conference 35
Jun 14, 2017: RespireRx Pharmaceuticals to Present at the 2017 Marcum MicroCap Conference 36
Jun 06, 2017: RespireRx Pharmaceuticals Announces Participation SLEEP 2017 in Boston, MA 37
Feb 10, 2017: RespireRx Pharmaceuticals to Present Data on CX-1739 at BIO CEO & Investor Conference 2017 38
Feb 10, 2017: RespireRx Pharmaceuticals to Present Data on dronabinol at BIO CEO & Investor Conference 2017 39
Jan 06, 2017: RespireRx Pharmaceuticals to Present Data on CX1739 at 9th Annual Biotech Showcase 2017 40
Jan 06, 2017: RespireRx Pharmaceuticals to Present Data on Dronabinol at 9th Annual Biotech Showcase 2017 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
RespireRx Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
RespireRx Pharma Raises Funds through in Venture Financing 11
RespireRx Pharma Raises USD0.1 Million in Financing 12
RespireRx Pharma Enters into Agreement Noramco 13
RespireRx Pharma Enters into Research Agreement with National Institute of Drug Abuse 14
Cortex Pharma Enters into Licensing Agreement with University of Illinois 15
Samyang Optics Enters into Licensing Agreement with Cortex Pharma 17
Cortex Pharma Raises USD0.7 Million in First Tranche of Private Placement of Units 18
Cortex Pharma Acquires Pier Pharma, Sleep Apnea Drug Development Company 19
RespireRx Pharmaceuticals Inc, Key Competitors 20
RespireRx Pharmaceuticals Inc, Key Employees 21
RespireRx Pharmaceuticals Inc, Subsidiaries 22

List of Figures
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[RespireRx Pharmaceuticals Inc (RSPI):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Enviva Partners LP (EVA):企業の財務・戦略的SWOT分析
    Enviva Partners LP (EVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • PetroChina Co Ltd (857):企業の財務・戦略的SWOT分析
    PetroChina Co Ltd (857) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Rosenergoatom Concern:企業の戦略的SWOT分析
    Rosenergoatom Concern - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Alphabet Inc:戦略・SWOT・企業財務分析
    Alphabet Inc - Strategy, SWOT and Corporate Finance Report Summary Alphabet Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Altria Group Inc (MO):企業の財務・戦略的SWOT分析
    Altria Group Inc (MO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Rubius Therapeutics Inc (RUBY):製薬・医療:M&Aディール及び事業提携情報
    Summary Rubius Therapeutics Inc (Rubius Therapeutics) is a biotechnology company that focuses on the development of medicines for the treatment of rare diseases, cancer and autoimmune diseases. The company through its rubius erythrocyte design (RED) platform engineer and culture Red Cell Therapeutic …
  • Gas2Grid Ltd (GGX):石油・ガス:M&Aディール及び事業提携情報
    Summary Gas2Grid Ltd (Gas2Grid) is an oil and gas company that offers exploration and development of conventional oil and gas onshore Cebu Island in the Philippines, Aquitaine Basin in south-west France and the Canning Basin, Australia. The company explores and develops conventional oil and gas, coa …
  • Albemarle Corporation:戦略・SWOT・企業財務分析
    Albemarle Corporation - Strategy, SWOT and Corporate Finance Report Summary Albemarle Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Depuy Synthes Companies:企業の戦略・SWOT・財務分析
    Depuy Synthes Companies - Strategy, SWOT and Corporate Finance Report Summary Depuy Synthes Companies - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Moldex-Metric Inc:企業の戦略的SWOT分析
    Moldex-Metric Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Assicurazioni Generali SpA:企業のM&A・事業提携・投資動向
    Assicurazioni Generali SpA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Assicurazioni Generali SpA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Cremonini S.p.A. (Foodservice):企業の戦略・SWOT・財務情報
    Cremonini S.p.A. (Foodservice) - Strategy, SWOT and Corporate Finance Report Summary Cremonini S.p.A. (Foodservice) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Kohler Co.:企業の戦略・SWOT・財務分析
    Kohler Co. - Strategy, SWOT and Corporate Finance Report Summary Kohler Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • DNO ASA (DNO):企業の財務・戦略的SWOT分析
    Summary DNO ASA (DNO) is an oil and gas company that provides mineral properties exploration and development services. The company's services include selective and targeted drilling, fractured carbonate plays that are characteristic of the MENA region. It operates its oil and gas producing assets lo …
  • Consumers Energy Co (CMS PR B):電力:M&Aディール及び事業提携情報
    Summary Consumers Energy Co (Consumers), formerly Consumers Power, is an electric and natural gas utility. The company generates purchases, transmits, distributes, and sells electricity. It also carries out the purchase, transmission, storage, distribution, and sale of natural gas. It generates elec …
  • Schneider Electric SE (SU):企業の財務・戦略的SWOT分析
    Schneider Electric SE (SU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Thermax Ltd (THERMAX):企業の財務・戦略的SWOT分析
    Thermax Ltd (THERMAX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Zynex Inc (ZYXI):企業の財務・戦略的SWOT分析
    Summary Zynex Inc (Zynex), formerly Zynex Medical Inc is a medical technology company that designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. The company’s products include NexWave, a dual channel, multi-modality interferential current, tra …
  • Select Medical Holdings Corporation:企業の戦略・SWOT・財務分析
    Select Medical Holdings Corporation - Strategy, SWOT and Corporate Finance Report Summary Select Medical Holdings Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • AIT Austrian Institute of Technology GmbH:医療機器:M&Aディール及び事業提携情報
    Summary AIT Austrian Institute of Technology GmbH (AIT) is a research and technology organisation which provides research and development services. The institute provides research and technological development for infrastructure related technologies in the fields of energy, mobility systems, low-emi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆